Pfizer's Stock Is Finally Showing Signs of Life. Could This Be the Start of a Much Bigger Rally?

Pfizer stock has gained 18% this year amid a potential rotation from tech to healthcare stocks. The company offers an attractive 5.8% dividend yield and trades at a forward P/E multiple of around 10, suggesting significant undervaluation despite a high trailing P/E of 37 due to restructuring charges. Analysts believe the stock has substantial upside potential as the market recognizes its value.